Ocular Therapeutix, Inc.
OCUL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,352 | $356 | $216 | $532 |
| - Cash | $392 | $196 | $102 | $164 |
| + Debt | $76 | $83 | $64 | $59 |
| Enterprise Value | $1,035 | $244 | $178 | $427 |
| Revenue | $64 | $58 | $51 | $44 |
| % Growth | 9% | 13.5% | 18.3% | – |
| Gross Profit | $58 | $53 | $47 | $39 |
| % Margin | 91.2% | 91% | 91.2% | 89.9% |
| EBITDA | -$176 | -$66 | -$62 | $3 |
| % Margin | -276.4% | -113.6% | -120.2% | 5.8% |
| Net Income | -$194 | -$81 | -$71 | -$7 |
| % Margin | -303.7% | -138.1% | -138% | -15.1% |
| EPS Diluted | -1.22 | -1.02 | -0.97 | -0.98 |
| % Growth | -19.6% | -5.2% | 1% | – |
| Operating Cash Flow | -$135 | -$70 | -$60 | -$66 |
| Capital Expenditures | -$1 | -$6 | -$4 | -$1 |
| Free Cash Flow | -$136 | -$76 | -$63 | -$67 |